{"entity":{"id":"ncc-japan","kind":"institution","name":"National Cancer Center Hospital","aka":[],"tldr":"The National Cancer Center Hospital is Japan's national cancer centre and the leading site for Daiichi Sankyo's DXd ADC trials.","summary":"The National Cancer Center Hospital in Tokyo is Japan's national cancer centre, a government institution ranked thirteenth in the Newsweek/Statista oncology list, with a sister campus at National Cancer Center Hospital East in Kashiwa. Together they run Japan's largest phase 1 programme and the SCRUM-Japan genomic screening network, and they led the early studies of Daiichi Sankyo's DXd antibody-drug conjugates, including trastuzumab deruxtecan and datopotamab deruxtecan, with Noboru Yamamoto, Ken Kato, Kohei Shitara and Kan Yonemori among their investigators. OnCo links the centre to CIRCULATE-Japan and the GALAXY paper, to SPOTLIGHT, to the Japan Clinical Oncology Group and the PMDA, and to the idea of one multiregional trial without bridging studies. Regulatory divergence between regions is the bottleneck its work most often meets. Its ADC programme is the reason to read on.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.ncc.go.jp/en/"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["trastuzumab-deruxtecan","datopotamab-deruxtecan"],"companies":["daiichi-sankyo"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["nakagama-hitoshi","yamamoto-noboru","kohno-takashi","ken-kato","yonemori-kan","shitara-kohei","goto-koichi","yoshino-takayuki","doi-toshihiko","ohe-yuichiro"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Tokyo","country":"JP","lat":35.665,"lng":139.767,"institutionType":"government","website":"https://www.ncc.go.jp/en/","newsweekOncology2026":13,"programs":["Phase 1 ADC trials","SCRUM-Japan","Proton therapy (East)"]},"route":"/institutions/ncc-japan/","neighbours":{"drug":[{"id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/"}],"company":[{"id":"daiichi-sankyo","kind":"company","name":"Daiichi Sankyo","route":"/companies/daiichi-sankyo/"},{"id":"jcog","kind":"company","name":"Japan Clinical Oncology Group (JCOG)","route":"/companies/jcog/"},{"id":"wjog","kind":"company","name":"West Japan Oncology Group","route":"/companies/wjog/"}],"person":[{"id":"fukuda-haruhiko","kind":"person","name":"Haruhiko Fukuda","route":"/people/fukuda-haruhiko/"},{"id":"hitoshi-katai","kind":"person","name":"Hitoshi Katai","route":"/people/hitoshi-katai/"},{"id":"nakagama-hitoshi","kind":"person","name":"Hitoshi Nakagama","route":"/people/nakagama-hitoshi/"},{"id":"yonemori-kan","kind":"person","name":"Kan Yonemori","route":"/people/yonemori-kan/"},{"id":"ken-kato","kind":"person","name":"Ken Kato","route":"/people/ken-kato/"},{"id":"shitara-kohei","kind":"person","name":"Kohei Shitara","route":"/people/shitara-kohei/"},{"id":"goto-koichi","kind":"person","name":"Koichi Goto","route":"/people/goto-koichi/"},{"id":"yamamoto-noboru","kind":"person","name":"Noboru Yamamoto","route":"/people/yamamoto-noboru/"},{"id":"kohno-takashi","kind":"person","name":"Takashi Kohno","route":"/people/kohno-takashi/"},{"id":"yoshino-takayuki","kind":"person","name":"Takayuki Yoshino","route":"/people/yoshino-takayuki/"},{"id":"doi-toshihiko","kind":"person","name":"Toshihiko Doi","route":"/people/doi-toshihiko/"},{"id":"ohe-yuichiro","kind":"person","name":"Yuichiro Ohe","route":"/people/ohe-yuichiro/"}],"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"}],"trial":[{"id":"altair","kind":"trial","name":"ALTAIR","route":"/trials/altair/"},{"id":"circulate-japan","kind":"trial","name":"CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)","route":"/trials/circulate-japan/"},{"id":"romana-1-2","kind":"trial","name":"ROMANA 1 and ROMANA 2","route":"/trials/romana-1-2/"},{"id":"triumph","kind":"trial","name":"TRIUMPH","route":"/trials/triumph/"}],"roadmap":[{"id":"colorectal-roadmap","kind":"roadmap","name":"Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation","route":"/roadmaps/colorectal-roadmap/"}],"paper":[{"id":"paper-hiraoka-her2-status-biliary-hum-pathol-2020","kind":"paper","name":"Details of human epidermal growth factor receptor 2 status in 454 cases of biliary tract cancer","route":"/key-papers/paper-hiraoka-her2-status-biliary-hum-pathol-2020/"},{"id":"paper-galaxy-signatera-nat-med-2023","kind":"paper","name":"GALAXY: tumour DNA in blood four weeks after bowel cancer surgery predicts relapse tenfold","route":"/key-papers/paper-galaxy-signatera-nat-med-2023/"},{"id":"paper-nakamura-biliary-genomic-spectra-nat-genet-2015","kind":"paper","name":"Genomic spectra of biliary tract cancer","route":"/key-papers/paper-nakamura-biliary-genomic-spectra-nat-genet-2015/"},{"id":"paper-spotlight-lancet-2023","kind":"paper","name":"SPOTLIGHT: zolbetuximab, the first Claudin 18.2 antibody, added to chemotherapy in gastric cancer","route":"/key-papers/paper-spotlight-lancet-2023/"},{"id":"paper-ohba-herb-trastuzumab-deruxtecan-biliary-jco-2024","kind":"paper","name":"Trastuzumab deruxtecan in human epidermal growth factor receptor 2-expressing biliary tract cancer (HERB; NCCH1805): a multicenter, single-arm, phase II trial","route":"/key-papers/paper-ohba-herb-trastuzumab-deruxtecan-biliary-jco-2024/"}],"bottleneck":[{"id":"b-regulatory-fragmentation","kind":"bottleneck","name":"Regulatory divergence between regions","route":"/bottlenecks/b-regulatory-fragmentation/"}],"idea":[{"id":"idea-fund-surgical-trials-network","kind":"idea","name":"A permanently funded international network for randomised cancer surgery trials","route":"/ideas/idea-fund-surgical-trials-network/"},{"id":"idea-bio2-anamorelin-access","kind":"idea","name":"Get the one approved appetite drug licensed beyond a single country","route":"/ideas/idea-bio2-anamorelin-access/"},{"id":"idea-reg-mrct-no-bridging","kind":"idea","name":"One multiregional trial, no bridging studies: enforce ICH E17 in Japan and China","route":"/ideas/idea-reg-mrct-no-bridging/"}],"collection":[{"id":"jsmo-jsco-guidelines","kind":"collection","name":"Japanese oncology guidelines (JSMO, JSCO and organ societies)","route":"/collections/jsmo-jsco-guidelines/"}],"technology":[{"id":"cachexia-appetite-pharmacotherapy","kind":"technology","name":"Cachexia pharmacotherapy: GDF-15 blockade, anamorelin, olanzapine","route":"/technologies/cachexia-appetite-pharmacotherapy/"}],"institution":[{"id":"jsmo","kind":"institution","name":"Japanese Society of Medical Oncology","route":"/institutions/jsmo/"},{"id":"kyushu-university-hospital","kind":"institution","name":"Kyushu University Hospital","route":"/institutions/kyushu-university-hospital/"},{"id":"ncc-hospital-east","kind":"institution","name":"National Cancer Center Hospital East","route":"/institutions/ncc-hospital-east/"},{"id":"pmda","kind":"institution","name":"Pharmaceuticals and Medical Devices Agency","route":"/institutions/pmda/"}]}}